Nefazodone treatment of pathological gambling: A prospective open-label controlled trial

Stefano Pallanti, Nicolò Baldini Rossi, Erica Sood, Eric Hollander

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Pathological gambling is a disabling and highly prevalent impulse-control disorder not otherwise specified (NOS). According to the hypothesis of abnormal serotonin function in the pathophysiology of poor impulse control and pathological gambling, we assessed the efficacy and tolerability of nefazodone, a 5-HT antagonist reported to be effective in other impulse-control disorders NOS, in the treatment of pathological gambling. Method: Fourteen outpatients who met DSM-IV criteria for pathological gambling were enrolled in a prospective 8-week open-label oral nefazodone trial. Nefazodone was initiated at 50 mg/day and titrated upward to a maximum of 500 mg/day based on patient's response and side effects, with a minimum daily dose of 100 mg. Improvement in gambling was assessed via the pathological gambling modifications of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS), the Clinical Global Impressions-Improvement scale (PG-CGI-I), and self-rated gambling scales. Response was defined a priori as both a 25% reduction in PG-YBOCS score and a score of 1 (very much improved) or 2 (much improved) on the PG-CGI-I scale. Results: Twelve subjects completed the study, and 2 subjects were early dropouts who did not receive the minimum required dose. Significant improvements were noted in all gambling outcome measures, as well as in depression and anxiety ratings (which did not significantly correlate with gambling reduction). Nine (75%) of 12 patients were rated as responders according to a priori criteria. Side effects (dry mouth and sedation) of moderate severity occurred in 4 subjects. Conclusion: These preliminary results suggest that nefazodone may be effective in reducing symptoms of pathological gambling and is well tolerated.

Original languageEnglish (US)
Pages (from-to)1034-1039
Number of pages6
JournalJournal of Clinical Psychiatry
Volume63
Issue number11
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Gambling
Therapeutics
Disruptive, Impulse Control, and Conduct Disorders
nefazodone
Conscious Sedation
Serotonin Antagonists
Diagnostic and Statistical Manual of Mental Disorders
Mouth
Serotonin
Outpatients
Anxiety
Outcome Assessment (Health Care)
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Nefazodone treatment of pathological gambling : A prospective open-label controlled trial. / Pallanti, Stefano; Rossi, Nicolò Baldini; Sood, Erica; Hollander, Eric.

In: Journal of Clinical Psychiatry, Vol. 63, No. 11, 11.2002, p. 1034-1039.

Research output: Contribution to journalArticle

Pallanti, Stefano ; Rossi, Nicolò Baldini ; Sood, Erica ; Hollander, Eric. / Nefazodone treatment of pathological gambling : A prospective open-label controlled trial. In: Journal of Clinical Psychiatry. 2002 ; Vol. 63, No. 11. pp. 1034-1039.
@article{bcfa0cd32a7b445892b0d97e5569bd0e,
title = "Nefazodone treatment of pathological gambling: A prospective open-label controlled trial",
abstract = "Background: Pathological gambling is a disabling and highly prevalent impulse-control disorder not otherwise specified (NOS). According to the hypothesis of abnormal serotonin function in the pathophysiology of poor impulse control and pathological gambling, we assessed the efficacy and tolerability of nefazodone, a 5-HT antagonist reported to be effective in other impulse-control disorders NOS, in the treatment of pathological gambling. Method: Fourteen outpatients who met DSM-IV criteria for pathological gambling were enrolled in a prospective 8-week open-label oral nefazodone trial. Nefazodone was initiated at 50 mg/day and titrated upward to a maximum of 500 mg/day based on patient's response and side effects, with a minimum daily dose of 100 mg. Improvement in gambling was assessed via the pathological gambling modifications of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS), the Clinical Global Impressions-Improvement scale (PG-CGI-I), and self-rated gambling scales. Response was defined a priori as both a 25{\%} reduction in PG-YBOCS score and a score of 1 (very much improved) or 2 (much improved) on the PG-CGI-I scale. Results: Twelve subjects completed the study, and 2 subjects were early dropouts who did not receive the minimum required dose. Significant improvements were noted in all gambling outcome measures, as well as in depression and anxiety ratings (which did not significantly correlate with gambling reduction). Nine (75{\%}) of 12 patients were rated as responders according to a priori criteria. Side effects (dry mouth and sedation) of moderate severity occurred in 4 subjects. Conclusion: These preliminary results suggest that nefazodone may be effective in reducing symptoms of pathological gambling and is well tolerated.",
author = "Stefano Pallanti and Rossi, {Nicol{\`o} Baldini} and Erica Sood and Eric Hollander",
year = "2002",
month = "11",
language = "English (US)",
volume = "63",
pages = "1034--1039",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - Nefazodone treatment of pathological gambling

T2 - A prospective open-label controlled trial

AU - Pallanti, Stefano

AU - Rossi, Nicolò Baldini

AU - Sood, Erica

AU - Hollander, Eric

PY - 2002/11

Y1 - 2002/11

N2 - Background: Pathological gambling is a disabling and highly prevalent impulse-control disorder not otherwise specified (NOS). According to the hypothesis of abnormal serotonin function in the pathophysiology of poor impulse control and pathological gambling, we assessed the efficacy and tolerability of nefazodone, a 5-HT antagonist reported to be effective in other impulse-control disorders NOS, in the treatment of pathological gambling. Method: Fourteen outpatients who met DSM-IV criteria for pathological gambling were enrolled in a prospective 8-week open-label oral nefazodone trial. Nefazodone was initiated at 50 mg/day and titrated upward to a maximum of 500 mg/day based on patient's response and side effects, with a minimum daily dose of 100 mg. Improvement in gambling was assessed via the pathological gambling modifications of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS), the Clinical Global Impressions-Improvement scale (PG-CGI-I), and self-rated gambling scales. Response was defined a priori as both a 25% reduction in PG-YBOCS score and a score of 1 (very much improved) or 2 (much improved) on the PG-CGI-I scale. Results: Twelve subjects completed the study, and 2 subjects were early dropouts who did not receive the minimum required dose. Significant improvements were noted in all gambling outcome measures, as well as in depression and anxiety ratings (which did not significantly correlate with gambling reduction). Nine (75%) of 12 patients were rated as responders according to a priori criteria. Side effects (dry mouth and sedation) of moderate severity occurred in 4 subjects. Conclusion: These preliminary results suggest that nefazodone may be effective in reducing symptoms of pathological gambling and is well tolerated.

AB - Background: Pathological gambling is a disabling and highly prevalent impulse-control disorder not otherwise specified (NOS). According to the hypothesis of abnormal serotonin function in the pathophysiology of poor impulse control and pathological gambling, we assessed the efficacy and tolerability of nefazodone, a 5-HT antagonist reported to be effective in other impulse-control disorders NOS, in the treatment of pathological gambling. Method: Fourteen outpatients who met DSM-IV criteria for pathological gambling were enrolled in a prospective 8-week open-label oral nefazodone trial. Nefazodone was initiated at 50 mg/day and titrated upward to a maximum of 500 mg/day based on patient's response and side effects, with a minimum daily dose of 100 mg. Improvement in gambling was assessed via the pathological gambling modifications of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS), the Clinical Global Impressions-Improvement scale (PG-CGI-I), and self-rated gambling scales. Response was defined a priori as both a 25% reduction in PG-YBOCS score and a score of 1 (very much improved) or 2 (much improved) on the PG-CGI-I scale. Results: Twelve subjects completed the study, and 2 subjects were early dropouts who did not receive the minimum required dose. Significant improvements were noted in all gambling outcome measures, as well as in depression and anxiety ratings (which did not significantly correlate with gambling reduction). Nine (75%) of 12 patients were rated as responders according to a priori criteria. Side effects (dry mouth and sedation) of moderate severity occurred in 4 subjects. Conclusion: These preliminary results suggest that nefazodone may be effective in reducing symptoms of pathological gambling and is well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0036854259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036854259&partnerID=8YFLogxK

M3 - Article

C2 - 12444818

AN - SCOPUS:0036854259

VL - 63

SP - 1034

EP - 1039

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -